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Detailed resource utilization data were collected for all patients from 8 countries 
(U.S.,Australia,Canada,Germany,Italy,Spain,UK and France; n  3373 prasugrel, n  
3332 clopidogrel). Hospitalization costs were estimated from the perspective of the 
German health care system on the basis of diagnosis-related groups (DRGs) for 
Germany and in-hospital complications. Costs for cardiovascular medications were 
estimated using public price per tablet (clopidogrel  a2.68/day; prasugrel  a2.94/
day). Life expectancy (LE) was estimated based on in-trial cardiovascular and bleeding 
events, using statistical models developed from a similar population from the Saskatch-
ewan Health Database. Costs in added years of life were not included in the base case. 
The analysis was carried out for the overall cohort and the 10 mg. recommended 
population of patients with no history of stroke/TIA, age  75 and body wt. 60kg. 
RESULTS: Over a median 14.5 month follow-up period, average total costs were 
a15/patient (a20/patient for the 10 mg. recommended population) lower with prasu-
grel, due to a lower rate of rehospitalization involving PCI. Prasugrel was associated 
with LE gains of 0.102 years (0.129 for the 10 mg. recommended population), due 
primarily to the decreased rate of non-fatal MI. Compared to clopidogrel, prasugrel 
was thus an economically dominant treatment strategy. When compared to generic 
clopidogrel at a cost of  a1.80/day, there was an incremental net cost with prasugrel 
of a281/patient (a285/patient for the 10 mg. recommended population), and an ICER 
of a2743/life year gained (a2213/life year gained for the 10 mg. recommended popula-
tion). CONCLUSIONS: For ACS patients with planned PCI, prasugrel for up to 15 
months compared with current standard of care is an economically attractive treat-
ment strategy.
PCV88
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OBJECTIVES: Ambrisentan, a non-sulphonamide endothelin receptor antagonist 
(ERA) was recently licensed for the treatment of Pulmonary Arterial Hypertension 
(PAH). The study objective was to estimate the cost-effectiveness of ambrisentan from 
an Irish Healthcare perspective. METHODS: A discrete event simulation model devel-
oped by United BioSource Corporation was used to compare the cost-effectiveness of 
ambrisentan relative to two other ERAs (bosentan, sitaxentan) over a ﬁve year time 
horizon. The probability of clinical worsening and liver abnormality events were pre-
dicted from regression equations derived from the ambrisentan clinical trials data. 
These regression equations were also used to predict events for the comparator thera-
pies by calibrating them to reproduce treatment effects consistent with those reported 
in the literature. Costs and utilities were then assigned to these events and were dis-
counted at 3.5%. Costs were obtained from Irish speciﬁc and UK sources and were 
in 2007 prices. Utility values were derived from ambrisentan clinical trials. RESULTS: 
It was estimated that ambrisentan is cost saving with improved health outcomes 
compared to both bosentan and sitaxentan; ambrisentan dominated both bosentan 
(a195,788/QALY) and sitaxentan (a138,780/QALY). This result was driven by the 
higher incidence of liver abnormalities associated with bosentan and sitaxentan com-
pared to ambrisentan. When patients experienced liver abnormalities a proportion of 
them switched to prostacylin therapy, which was more expensive and associated with 
lower QALYs than ERA therapy. Probabilistic sensitivity analysis revealed that the 
likelihood of ambrisentan dominating bosentan and sitaxentan was 86% and 73%, 
respectively. CONCLUSIONS: Ambrisentan is a cost-effective alternative for the treat-
ment of PAH in Ireland. This is because it results in a lower incidence of liver abnor-
malities compared to existing ERAs.
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OBJECTIVES: In patients with acute coronary syndromes (ACS) undergoing percu-
taneous coronary intervention (PCI), the TRITON-TIMI 38 trial (TTT) demonstrated 
that treatment with prasugrel vs. clopidogrel signiﬁcantly reduced rates of athero-
thrombotic events, though with increased risk of bleeding. We evaluated the long-term 
cost-effectiveness of this approach in patients free of stroke or TIA, from the perspec-
tive of the UK National Health Service. METHODS: A Markov model was developed 
based on risk equations for cardiovascular death, myocardial infarction (MI) or stroke, 
bleeding, and rehospitalisation, derived from TTT (N  13,608 patients). Hospital 
readmissions captured during the trial in all patients from 8 countries (N  6,705) 
were assigned to UK diagnosis related groups. After 12 months, common rehospitali-
sation costs were modelled to accrue over the life-time time horizon. RESULTS: 
During the ﬁrst year incremental drug cost of prasugrel (£162/patient) was partially 
offset by hospital cost savings (£14/patient) due principally to reduced revasculariza-
tion rates. Over the longer-term, prasugrel was associated with higher total costs 
resulting from rehospitalisations among survivors, of £169/patient, with life expec-
tancy gains of 0.06 years primarily due to reduced rate of MI, and 0.05 additional 
QALYs. Incremental cost per life year gained and per QALY gained were £2,606 and 
£3435 respectively. These results were consistent across subgroups, with incremental 
costs per QALY gained of £4494 in UA/NSTEMI, £2167 in STEMI, and £3461 in 
patients without any of three risk factors for bleeding (prior TIA/stroke, weight  
60kg, age q 75 years). Probabilistic sensitivity analysis indicated a 72% probability         
of prasugrel being cost-effective compared with branded clopidogrel at a willingness 
to pay of £20,000 per QALY. CONCLUSIONS: Prasugrel treatment to 1 year in 
ACS-PCI patients appears cost-effective compared with branded clopidogrel.
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OBJECTIVES: Literature shows that patients admitted to the intensive care unit (ICU) 
after cardiopulmonary resuscitation (CPR) have a worse clinical and economic 
outcome in terms of increased length of stay (LOS) in the ICU and a high mortality. 
In this study we investigated survival, health-related quality of life (HRQOL), costs 
and cost-effectiveness of patients admitted to the ICU after CPR. METHODS: A pro-
spective observational cohort analysis was performed. In the period of March 3– 
November 3, 2008, all consecutive patients admitted to the ICU after CPR necessitating 
mechanical ventilation were screened for inclusion. All data concerning demography, 
comorbidity, severity of disease, organ failure, ICU and hospital LOS were analyzed. 
Data concerning costs were restricted to hospital-related costs and further to direct 
costs. HRQOL before admission and 3 months after ICU-discharge was assessed using 
standardized questionnaires (EuroQoL 5D, Short Form-36 scores). Statistical signiﬁ-
cance was attained at P  0.05. RESULTS: Out of 39 patients admitted because of 
CPR, 35 patients (66% males) with a mean age of 62 years (SD 14.6) and APACHE 
II-score of 26.9 (SD 9) were included. Mortality was 57%. The 15 patients that 
survived had an equal HRQOL before and after ICU-discharge concerning pain 
(P  0.6), general health (P  0.2), vitality (P  0.1), role-emotional (P  0.1) and 
mental health (P  0.9). HRQOL was diminished on physical functioning (P  0.01), 
role-physical (P  0.007) and social functioning (P  0.02). Costs per hospital survivor 
were a92,139, and a6,399/quality adjusted life year (QALY). A sensitivity-analysis 
conﬁrmed the cost-effectiveness of ICU treatment after CPR. CONCLUSIONS: 
Mortality after CPR was high and comparable with data from literature. After 
three months, HRQOL was only worse when looking at physical level. Treatment 
after CPR necessitating mechanical ventilation was found to be a cost-effective 
intervention.
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OBJECTIVES: ExTRACT-TIMI 25 is a prospective randomized trial of 20,479 
patients with 1,279 recruited in Spain. The use of enoxaparin as adjunctive therapy 
for ﬁbrinolysis in patients with ST-segment elevation myocardial infarction versus 
unfractionated heparin (UFH) resulted in a 17% relative risk reduction of death or 
non-fatal myocardial infarction (MI). Using results from the ExTRACT-TIMI 25 trial 
we conducted an economic evaluation to estimate the cost-effectiveness of enoxaparin 
in Spain. METHODS: Cost-effectiveness analysis was performed from the Spanish 
National Health Service perspective. Health resource data were obtained from the 
ExTRACT-TIMI 25 trial, coding according to Diagnostic Related Groups (DRGs). 
Medical direct costs data (procedures and drugs) were obtained from published 
Spanish literature. Survival and life expectancy were estimated from the Framingham 
Heart Study. Results are presented as incremental cost per life year gained (LYG) and 
cost per Quality Adjusted Life Years (QALY). To prove the robustness of the results 
we calculated 95% conﬁdence intervals for both costs and results. Long-term costs 
were discounted at 3% annually after the ﬁrst year. RESULTS: Considering short-term 
treatment results (30 days), enoxaparin achieved better results with more LYG than 
UFH but there was a not signiﬁcant difference in total costs. The incremental cost-
effectiveness ratio for enoxaparin obtained from the 30 days analysis was a977.5/
LYG. When long-term (lifelong) analysis was performed the cost obtained was of 
a2755.6/LYG and a3442.3/QALY. CONCLUSIONS: Considering the usual “willing-
ness to pay” cost-effectiveness threshold in Spain (a30,000 per LYG and per QALY) 
enoxaparin administered as adjunctive therapy for ﬁbrinolysis in ST-elevation myo-      
cardial infarction patients is a potentially cost-effective strategy compared with UFH 
in Spain.
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OBJECTIVES: Exercise training is an effective strategy to reduce combined clinical 
outcomes in heart failure (HF). Nonetheless, implementation of such programs 
has been restricted to university and specialized centers. Economic analysis of this 
